Navigation Links
1 size may not fit all
Date:10/29/2007

INDIANAPOLIS While colonoscopy has become widely used for colorectal cancer screening, nearly two-thirds of screening colonoscopies show no cancer or pre-cancerous polyps. In an editorial in the October issue of the journal Gastroenterology, Thomas F. Imperiale, M.D., professor of medicine at the Indiana University School of Medicine and a Regenstrief Institute, Inc. research scientist, says that studies that can help determine who is at risk for colorectal cancer as well as who is not at risk and how to stratify risk for each group can help determine which screening test is best for each individual and will better serve both patients and the healthcare system.

If we knew more about risk factors for advanced neoplasia [cancer and advanced, precancerous polyps] and could effectively stratify risk, then screening and surveillance could be tailoredthat is, targeted to persons with high risk and away from those at low risk, who could either be examined with less invasive methods or perhaps not at all. Risk stratification and tailoring would improve the overall efficiency and effectiveness of colonoscopic screening and surveillance, Dr Imperiale wrote.

Dr. Imperiale is the lead investigator of the Risk Assessment in Colon Cancer Study, which is investigating whether using easily accessible factors such as age, family medical history, race, smoking history, body mass index, and other candidate factors can help determine who is and who is not at risk. That study also focuses on whether more sophisticated tools such as blood tests that look at genes, proteins or other markers of risk, would be effective.

Colonoscopy has become a common tool for screening partly by default, according to Dr. Imperiale.

Colonoscopy is the 500-pound gorilla. It has evolved into an acceptable screening test in part because many people believe that there are no other good options. To increase screening rates for colorectal cancers, we need to stress convenient and less invasive screening tests for those who are not at high risk for colorectal cancer and advanced, precancerous polyps, said Dr. Imperiale. First, however, we need a way to stratify risk among the nearly 90 percent of persons who are considered to be average-risk. Certainly, a hundred years from now - perhaps even 10 years from now screening colonoscopy will likely be looked upon as overkill, said Dr. Imperiale, who is a gastroenterologist and clinical epidemiologist.


'/>"/>

Contact: Cindy Fox Aisen
caisen@iupui.edu
317-274-7722
Indiana University
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology: